FDAnews Announces Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19 Webinar March 18, 2021
Share Article
Is the pandemic making postmarket surveillance even more difficult? Two former FDAers explain how to comply. Register today.
WCG FDAnews Pharmaceutical Postmarket Surveillance:
An FDAnews Webinar
Are you confident you’re compliant with current FDA postmarket adverse event reporting regulations? Postmarket surveillance can be difficult during the best of times. And in the COVID-19 era it’s become even more difficult.
Cynthia Schnedar, Executive Vice President of Regulatory Compliance at Greenleaf Health and former Director of the Office of Compliance for FDA’s Center for Drug Evaluation and Research (CDER) and Dawn Wynder, a Project Manager for FDAQRC and a former FDA Investigator, will ensure attendees understand how the FDA conducts its postmarket safety surveillance and what one must do to ensure postmarket adverse reporting inspe